All Updates

All Updates

icon
Filter
Funding
Freedom Biosciences launches with USD 10.5 million in seed funding
Psychedelic Medicine
Aug 23, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Aug 23, 2022

Freedom Biosciences launches with USD 10.5 million in seed funding

Funding

  • California-based psychedelic biotechnology company Freedom Biosciences has emerged from stealth, raising USD 10.5 million in a seed funding round led by MBX Capital, with participation from PsyMed Ventures, Village Global, and The Yale Startup. 

  • The proceeds from the round will be directed toward advancing its psychedelic therapy programs, including its lead ketamine-based therapy FREE001. 

  • Founded in 2021, Freedom Biosciences develops psychedelic-based combination therapeutics for mental health disorders such as major depressive disorder (MDD). The company’s drug discovery platform leverages the already-known pharmacology of ketamine and other psychedelics to identify new therapies that are expected to be more effective than existing ketamine and psychedelic therapies that are administered alone.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.